Moderna is still fending off patent challenges over the lipid nanoparticle delivery system used in the company’s COVID-19 vaccine, Spikevax.
Janssen Victorious in Arbitration Battle Vs. Genmab over Darzalex Royalties
Expirations, FDA, Janssen, Johnson & Johnson, Multiple Myeloma, Patent, Patent Challenges, Patent Claims, Patent Disputes, Patent Exclusivity, Patent Expirations, Patent Infringement, Patent Lawsuits, Patent Licensing, Patent Litigation, Patent Protection, Patents, Therapeutics, U.S. Patent OfficeApr 08, 2022 By Jazmine Colatriano, M.S. BioSpace Johnson & Johnson’s Janssen Pharmaceutical secured an arbitrary win regarding royalty decisions stemming from the licensing and marketing of daratumumab, an anti-CD38 monoclonal antibody treatment that has multiple indications approved by the U.S. Food and Drug Administration (FDA). The confidential arbitration was conducted by a tribunal of three earlier this […]
Moderna is facing additional challenges to patent the COVID-19 vaccine Spikevax, as Arbutus Biopharma and Genevant filed a lawsuit against the company challenging patent infringement.
Gilead Sciences lost yet another challenge to the company’s U.S. patent to Truvada for HIV prevention, or PrEP.
Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis
Blockbusters, Bruton's Tyrosine Kinase (BTK) Inhibitors, Business, Clinical Trial Endpoints, Clinical Trials, CNS damage, MS with walking impairment, Multiple Sclerosis, Neurology, Patent Challenges, R&D, Secondary Endpoints, Shares, U.S. Patent Trial and Appeal Board (PTAB)Biogen successfully fended off a patent challenge from generic company Mylan over the multiple sclerosis (MS) drug Tecfidera.
Alexion Pharmaceuticals Inc. agreed to buy smaller biotech company Achillion Pharmaceuticals Inc. in a deal initially valued at $930 million.
A U.S. judge upheld two patents relating to Amgen Inc.’s blockbuster rheumatoid arthritis drug Enbrel, denying a challenge by Novartis AG, which is seeking to launch a copycat version.
The U.S. patent office rejected a filing by Alvogen Pine Brook for a review challenging patents on Celgene’s blockbuster myeloma drug Revlimid.
Amgen Inc. said a U.S. jury confirmed the validity of patents on the biotech company’s cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc. and Sanofi SA.